Your session is about to expire
← Back to Search
Gene Transfer Agent
RetinoStat® Safety for Age-Related Macular Degeneration
Phase 1
Waitlist Available
Led By Peter Campochiaro, MD
Research Sponsored by Oxford BioMedica
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must have received a subretinal injection of RetinoStat
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights
Study Summary
This trial will test the long-term safety of a new gene therapy for age-related macular degeneration.
Who is the study for?
This trial is specifically for patients who were previously enrolled in the RS1/001/10 study and received a subretinal injection of RetinoStat®. It's designed to follow up on those individuals to assess long-term safety related to their treatment for age-related macular degeneration.Check my eligibility
What is being tested?
The focus of this study is on the long-term safety profile of RetinoStat®, an experimental gene therapy aimed at treating neovascular age-related macular degeneration, which was administered in a prior clinical trial.See study design
What are the potential side effects?
Since this is a follow-up study, it will monitor for any delayed side effects from the initial RetinoStat® treatment. Specific side effects are not listed but may pertain to eye health and vision changes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have received a RetinoStat injection in my eye.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The incidence of adverse events
Secondary outcome measures
The change from baseline in BCVA.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Long Term Follow upExperimental Treatment1 Intervention
Long Term follow up of patients who received RetinoStat in a previous study.
Find a Location
Who is running the clinical trial?
Oxford BioMedicaLead Sponsor
12 Previous Clinical Trials
1,039 Total Patients Enrolled
Peter Campochiaro, MDPrincipal InvestigatorJohn Hopkins University Hospital
5 Previous Clinical Trials
235 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have received a RetinoStat injection in my eye.
Research Study Groups:
This trial has the following groups:- Group 1: Long Term Follow up
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there available positions for participants in this clinical trial?
"At this time, the research study listed on clinicaltrials.gov is not in search of potential candidates. This trial was initially published August 1st 2012 and modified November 7th 2022 but it does not seem to be currently enrolling patients at present; however, there are other 159 trials actively recruiting people now."
Answered by AI
What safety protocols are in place for this therapeutic intervention?
"The safety of this intervention is rated 1 on our scale due to it being in Phase 1, leaving limited evidence for its efficacy and safety."
Answered by AI
Who else is applying?
What state do they live in?
Iowa
What site did they apply to?
University of Iowa Hospitals & Clinics
What portion of applicants met pre-screening criteria?
Met criteria
Share this study with friends
Copy Link
Messenger